BR112017009817A2 - anticorpos anti-il-1beta e métodos de utilização - Google Patents
anticorpos anti-il-1beta e métodos de utilizaçãoInfo
- Publication number
- BR112017009817A2 BR112017009817A2 BR112017009817A BR112017009817A BR112017009817A2 BR 112017009817 A2 BR112017009817 A2 BR 112017009817A2 BR 112017009817 A BR112017009817 A BR 112017009817A BR 112017009817 A BR112017009817 A BR 112017009817A BR 112017009817 A2 BR112017009817 A2 BR 112017009817A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- 1beta
- hvr
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
descrevem-se neste contexto anticorpos anti-il-1betas humanizados os quais são compreendidos por variantes humanizadas do anticorpo anti-il-1beta h34 de murídeo. um anticorpo humanizado específico compreende (a) uma hvr-h1 que compreende a sequência de aminoácidos de seq id no: 25, (b) uma hvr-h2 que compreende a sequência de aminoácidos de seq id no: 27, e (c) uma hvr-h3 que compreende a sequência de aminoácidos de seq id no: 28.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14192523 | 2014-11-10 | ||
PCT/EP2015/075875 WO2016075034A1 (en) | 2014-11-10 | 2015-11-06 | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017009817A2 true BR112017009817A2 (pt) | 2018-02-14 |
Family
ID=51868114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017009817A BR112017009817A2 (pt) | 2014-11-10 | 2015-11-06 | anticorpos anti-il-1beta e métodos de utilização |
Country Status (15)
Country | Link |
---|---|
US (1) | US10344085B2 (pt) |
EP (1) | EP3218402A1 (pt) |
JP (1) | JP6787888B2 (pt) |
KR (1) | KR20170081253A (pt) |
CN (1) | CN107074942A (pt) |
AR (1) | AR102594A1 (pt) |
AU (1) | AU2015345320A1 (pt) |
BR (1) | BR112017009817A2 (pt) |
CA (1) | CA2963719A1 (pt) |
IL (1) | IL251165A0 (pt) |
MX (1) | MX2017005987A (pt) |
RU (1) | RU2017120358A (pt) |
SG (1) | SG11201702550WA (pt) |
TW (1) | TW201632552A (pt) |
WO (1) | WO2016075034A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016075036A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-pdgf-b antibodies and methods of use |
JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二重特異性抗体及び眼科に使用する方法 |
CA2963606A1 (en) | 2014-11-10 | 2016-05-19 | F.Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
RU2017120358A (ru) | 2014-11-10 | 2018-12-13 | Ф.Хоффманн-Ля Рош Аг | Анти-il-1-бета антитела и способы их применения |
WO2018212556A1 (en) * | 2017-05-16 | 2018-11-22 | Cj Healthcare Corporation | A method for purifying an antibody or an antibody fragment thereof using affinity chromatography |
AR111761A1 (es) * | 2017-05-16 | 2019-08-14 | Cj Healthcare Corp | Un método para purificar un anticuerpo o un fragmento de anticuerpo de este usando cromatografía de afinidad |
JP2020527332A (ja) | 2017-06-12 | 2020-09-10 | ブルーフィン バイオメディシン, インコーポレイテッド | 抗−il1rap抗体および抗体薬物コンジュゲート |
CA3089602A1 (en) | 2018-01-26 | 2019-08-01 | Genzyme Corporation | Fc variants with enhanced binding to fcrn and prolonged half-life |
CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
US11130804B2 (en) | 2018-12-21 | 2021-09-28 | Hoffmann-La Roche Inc. | Antibody that binds to VEGF and IL-1beta and methods of use |
CN117024587A (zh) * | 2019-03-07 | 2023-11-10 | 瑞阳(苏州)生物科技有限公司 | 人IL-1β蛋白结合分子及其编码基因和应用 |
KR102560876B1 (ko) * | 2019-06-11 | 2023-07-28 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 항-epcam 항체, 항체 단편, 이들의 면역접합체 및 이의 용도 |
CN114524875B (zh) * | 2021-11-11 | 2023-07-25 | 江苏莱森生物科技研究院有限公司 | 偶联IL-1β单克隆抗体的纳米硅球及应用 |
CN117126278B (zh) * | 2023-10-26 | 2024-01-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种单克隆抗体及其应用 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
WO2003073982A2 (en) * | 2002-02-28 | 2003-09-12 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
AU2004207741B2 (en) * | 2003-01-24 | 2011-02-10 | Applied Molecular Evolution, Inc | Human IL-1 beta antagonists |
US20050226863A1 (en) * | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
US20050282233A1 (en) | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
KR20110110349A (ko) * | 2009-01-29 | 2011-10-06 | 아보트 러보러터리즈 | Il-1 결합 단백질 |
CA2775402A1 (en) * | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Il-1 binding proteins |
TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
MX2013001267A (es) * | 2010-08-13 | 2013-04-10 | Genentech Inc | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. |
CN103328511B (zh) * | 2010-09-10 | 2016-01-20 | 埃派斯进有限公司 | 抗-IL-1β抗体及其使用方法 |
CA2821976A1 (en) * | 2010-12-21 | 2012-09-13 | Abbvie Inc. | Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use |
EP2726088B1 (en) | 2011-06-29 | 2019-01-02 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
EP2867360B1 (en) | 2012-06-28 | 2019-05-08 | Molecular Partners AG | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
LT3495387T (lt) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
BR112015006363A2 (pt) | 2012-09-28 | 2017-08-08 | Boehringer Ingelheim Int | combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r |
AU2013322564A1 (en) | 2012-09-28 | 2015-03-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual Angiopoietin-2 / Dll4 binders and anti-VEGF agents |
KR20210133321A (ko) | 2012-11-08 | 2021-11-05 | 클리어사이드 바이오메디컬, 인코포레이드 | 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치 |
WO2014072876A1 (en) | 2012-11-09 | 2014-05-15 | Pfizer Inc. | Platelet-derived growth factor b specific antibodies and compositions and uses thereof |
JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
AU2014227732A1 (en) * | 2013-03-15 | 2015-09-17 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 beta and IL-17 |
KR20210094669A (ko) * | 2013-04-29 | 2021-07-29 | 에프. 호프만-라 로슈 아게 | 인간 fcrn-결합 변형된 항체 및 사용 방법 |
EP3082857B1 (en) | 2013-12-20 | 2018-07-25 | F. Hoffmann-La Roche AG | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
JP6786392B2 (ja) | 2014-01-15 | 2020-11-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | FcRn結合特性が改変され、プロテインA結合特性が保持されているFc領域変異体 |
CA2963606A1 (en) | 2014-11-10 | 2016-05-19 | F.Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二重特異性抗体及び眼科に使用する方法 |
WO2016075036A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Anti-pdgf-b antibodies and methods of use |
RU2017120358A (ru) | 2014-11-10 | 2018-12-13 | Ф.Хоффманн-Ля Рош Аг | Анти-il-1-бета антитела и способы их применения |
WO2016209972A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
US11198726B2 (en) | 2017-06-02 | 2021-12-14 | Boerhinger Ingelheim International Gmbh | Anti-cancer combination therapy |
-
2015
- 2015-11-06 RU RU2017120358A patent/RU2017120358A/ru not_active Application Discontinuation
- 2015-11-06 KR KR1020177015590A patent/KR20170081253A/ko unknown
- 2015-11-06 WO PCT/EP2015/075875 patent/WO2016075034A1/en active Application Filing
- 2015-11-06 JP JP2017525023A patent/JP6787888B2/ja active Active
- 2015-11-06 SG SG11201702550WA patent/SG11201702550WA/en unknown
- 2015-11-06 CN CN201580060880.4A patent/CN107074942A/zh active Pending
- 2015-11-06 BR BR112017009817A patent/BR112017009817A2/pt not_active Application Discontinuation
- 2015-11-06 CA CA2963719A patent/CA2963719A1/en not_active Abandoned
- 2015-11-06 MX MX2017005987A patent/MX2017005987A/es unknown
- 2015-11-06 AU AU2015345320A patent/AU2015345320A1/en not_active Abandoned
- 2015-11-06 EP EP15790945.8A patent/EP3218402A1/en not_active Withdrawn
- 2015-11-09 TW TW104136907A patent/TW201632552A/zh unknown
- 2015-11-09 AR ARP150103647A patent/AR102594A1/es unknown
-
2017
- 2017-03-14 IL IL251165A patent/IL251165A0/en unknown
- 2017-05-09 US US15/590,161 patent/US10344085B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2017120358A3 (pt) | 2019-05-29 |
AU2015345320A1 (en) | 2017-04-06 |
RU2017120358A (ru) | 2018-12-13 |
JP2017534646A (ja) | 2017-11-24 |
US20170247447A1 (en) | 2017-08-31 |
TW201632552A (zh) | 2016-09-16 |
EP3218402A1 (en) | 2017-09-20 |
US10344085B2 (en) | 2019-07-09 |
IL251165A0 (en) | 2017-04-30 |
SG11201702550WA (en) | 2017-04-27 |
MX2017005987A (es) | 2017-06-29 |
KR20170081253A (ko) | 2017-07-11 |
WO2016075034A1 (en) | 2016-05-19 |
CA2963719A1 (en) | 2016-05-19 |
JP6787888B2 (ja) | 2020-11-18 |
AR102594A1 (es) | 2017-03-08 |
CN107074942A (zh) | 2017-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização | |
ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
AR110321A1 (es) | Anticuerpos antitau y métodos de uso | |
PE20180317A1 (es) | Anticuerpos anti-tau y metodos de uso | |
BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
PE20181336A1 (es) | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos | |
PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
MY198059A (en) | Anti-ox40 antibodies and their uses | |
BR112018006579A2 (pt) | anticorpos anti-humanos cd19 humanizados e métodos de uso | |
NZ762843A (en) | Anti-egfr antibodies and antibody drug conjugates | |
BR112017007170A2 (pt) | anticorpos anti-ox40 humanizados e suas utilizações | |
AR099855A1 (es) | Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
PE20240365A1 (es) | Anticuerpos anti-c5 y metodos de uso | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
MX2016012124A (es) | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. | |
PH12016501937A1 (en) | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
MX2023006415A (es) | Anticuerpos, usos y metodos. | |
AR078377A1 (es) | Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso | |
EA201890340A1 (ru) | Моноклональное антитело-ингибитор фактора xiia | |
CU24556B1 (es) | Anticuerpos anti-basigin humanizados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |